162 related articles for article (PubMed ID: 36239545)
21. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
[TBL] [Abstract][Full Text] [Related]
22. Tumor characteristics, expressions of ERCC1, Bax, p53, IGF1R, Bcl2, Bcl2/Bax and prognostic factors for overall survival in patients with lung carcinoid.
Velinovic M; Jankovic R; Jovanovic D; Skodric Trifunovic V; Gavrilovic D; Stojsic J; Cavic M
J BUON; 2019; 24(1):256-266. PubMed ID: 30941978
[TBL] [Abstract][Full Text] [Related]
23. The occurrence and associated risk factors of brain metastases in well differentiated grade 1 and 2 bronchial neuroendocrine tumours: A single centre retrospective analysis of 280 patients.
Spurgeon L; Jones J; Lewis A; Rammohan K; Shaheen F; Weaver J; Papaxoinis G; Mansoor W
J Neuroendocrinol; 2022 Jul; 34(7):e13180. PubMed ID: 35894811
[TBL] [Abstract][Full Text] [Related]
24. Pulmonary carcinoid tumours: A multi-centre analysis of survival and predictors of outcome following sublobar, lobar, and extended pulmonary resections.
Thakur S; Florisson D; Telianidis S; Yaftian N; Lee J; Knight S; Barnett S; Seevanayagam S; Antippa P; Alam N; Wright G
Asian Cardiovasc Thorac Ann; 2021 Jul; 29(6):532-540. PubMed ID: 33853389
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological indicators of survival among patients with pulmonary carcinoid tumor.
Vesterinen T; Mononen S; Salmenkivi K; Mustonen H; Räsänen J; Salo JA; Ilonen I; Knuuttila A; Haglund C; Arola J
Acta Oncol; 2018 Aug; 57(8):1109-1116. PubMed ID: 29463166
[TBL] [Abstract][Full Text] [Related]
26. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
[TBL] [Abstract][Full Text] [Related]
27. [Retrospective study of clinicopathological characteristics in bronchopulmonary carcinoid].
Liao H; Rao H; Zhang X; Lin Y; Jie M; Fu J; Long H; Rong T; Lin P
Zhongguo Fei Ai Za Zhi; 2010 Jun; 13(6):591-7. PubMed ID: 20681445
[TBL] [Abstract][Full Text] [Related]
28. Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids.
Swarts DR; Rudelius M; Claessen SM; Cleutjens JP; Seidl S; Volante M; Ramaekers FC; Speel EJ
Histopathology; 2017 Feb; 70(3):412-422. PubMed ID: 27701763
[TBL] [Abstract][Full Text] [Related]
29. Orthopedia homeobox protein (OTP) is a sensitive and specific marker for primary pulmonary carcinoid tumors in cytologic and surgical specimens.
Viswanathan K; Borczuk AC; Siddiqui MT
J Am Soc Cytopathol; 2019; 8(1):39-46. PubMed ID: 30929758
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of histopathological factors in survival and recurrence of atypical carcinoid tumours.
García-Fontán EM; Cañizares-Carretero MÁ; Blanco-Ramos M; Matilla-González JM; Carrasco-Rodríguez R; Barreiro-Morandeira F; García-Yuste M;
Interact Cardiovasc Thorac Surg; 2021 May; 32(6):904-910. PubMed ID: 33580683
[TBL] [Abstract][Full Text] [Related]
31. Partitioning of bronchopulmonary carcinoids in two different prognostic categories by ki-67 score.
Grimaldi F; Muser D; Beltrami CA; Machin P; Morelli A; Pizzolitto S; Talmassons G; Marciello F; Colao AA; Monaco R; Monaco G; Faggiano A
Front Endocrinol (Lausanne); 2011; 2():20. PubMed ID: 22654796
[TBL] [Abstract][Full Text] [Related]
32. What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?
Pelosi G; Fabbri A; Cossa M; Sonzogni A; Valeri B; Righi L; Papotti M
Semin Diagn Pathol; 2015 Nov; 32(6):469-79. PubMed ID: 26561395
[TBL] [Abstract][Full Text] [Related]
33. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
[TBL] [Abstract][Full Text] [Related]
34. Incidence and Prognostic Significance of Carcinoid Lymph Node Metastases.
Kneuertz PJ; Kamel MK; Stiles BM; Lee BE; Rahouma M; Harrison SW; Altorki NK; Port JL
Ann Thorac Surg; 2018 Oct; 106(4):981-988. PubMed ID: 29908980
[TBL] [Abstract][Full Text] [Related]
35. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
36. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties.
Kankava K; Maisonneuve P; Mangogna A; Centonze G; Cattaneo L; Prinzi N; Pusceddu S; Fazio N; Pisa E; Di Domenico S; Bertani E; Mazzaferro V; Albertelli M; Grillo F; Milione M
J Neuroendocrinol; 2021 Aug; 33(8):e13000. PubMed ID: 34268808
[TBL] [Abstract][Full Text] [Related]
37. Prognostic score for survival with pulmonary carcinoids: the importance of associating clinical with pathological characteristics.
Chiappetta M; Sperduti I; Ciavarella LP; Leuzzi G; Bria E; Mucilli F; Lococo F; Filosso P; Ratto G; Spaggiari L; Facciolo F; Margaritora S
Interact Cardiovasc Thorac Surg; 2020 Sep; 31(3):315-323. PubMed ID: 32747930
[TBL] [Abstract][Full Text] [Related]
38. Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group.
Filosso PL; Guerrera F; Evangelista A; Welter S; Thomas P; Casado PM; Rendina EA; Venuta F; Ampollini L; Brunelli A; Stella F; Nosotti M; Raveglia F; Larocca V; Rena O; Margaritora S; Ardissone F; Travis WD; Sarkaria I; Sagan D;
Eur J Cardiothorac Surg; 2015 Sep; 48(3):441-7; discussion 447. PubMed ID: 25564217
[TBL] [Abstract][Full Text] [Related]
39. The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence.
Marchevsky AM; Hendifar A; Walts AE
Mod Pathol; 2018 Oct; 31(10):1523-1531. PubMed ID: 29802361
[TBL] [Abstract][Full Text] [Related]
40. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis.
Milione M; Maisonneuve P; Grillo F; Mangogna A; Centonze G; Prinzi N; Pusceddu S; Garzone G; Cattaneo L; Busico A; Bossi P; Spaggiari P; Pellegrinelli A; Del Gobbo A; Ferrero S; Kankava K; Pruneri G; Rolli L; Roca E; Bercich L; Tironi A; Benvenuti MR; Gallazzi MS; Romano R; Berruti A; Pastorino U; Capella C
Neuroendocrinology; 2021; 111(5):475-489. PubMed ID: 32365350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
